GHRH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
==== Beginning of the conflict ==== The report claimed that open hostilities started "... with a large-scale Georgian military operation against the town of Tskhinvali and the surrounding areas, launched in the night of 7 to 8 August 2008", but "... any explanation of the origins of the conflict cannot focus solely on the artillery attack on Tskhinvali in the night of 7/8 August", since "... it was only the culminating point of a long period of increasing tensions, provocations and incidents", and there was "... no way to assign overall responsibility for the conflict to one side alone." The beginning of the armed conflict between Georgia and South Ossetia was dated by the commission to 7 August 2008 at 23.35; however, the commission acknowledged that "a violent conflict had already been going on before in South Ossetia", and "President Saakashvili's order on 7 August 2008 at 23.35 and the ensuing military attack on Tskhinvali [...] has to be seen as but one element in an on-going chain of events for military violence had also been reported before the outbreak of the open hostilities on 7 August 2008." It is believed that direct military confrontation between Russia and Georgia began on 8 August 2008.
=== Pharmacy === Cincinnati College of Pharmacy was established as the first pharmacy college west of the Alleghenies in 1850. It operated independently until 1954, then integrated into the University of Cincinnati in 1954. In 1967, the College of Pharmacy became a unit of the University of Cincinnati Academic Health Center. On June 6, 2007, the College of Pharmacy changed its name to the James L. Winkle College of Pharmacy, for alumnus Jim Winkle. The college is only the second in UC's history to be named to honor a supporter.
== Veterinary use == Sufentanil is used both as an analgesic and as part of an anaesthetic protocol. In cats the half-life of sufentanil is longer than that of fentanyl and alfentanil. In dogs sufentanil produces a better anaesthetic recovery with similar analgesic and respiratory depression than fentanyl. One report suggest that for post-operative pain bupivacaine and sufentanil provides greater analgesia than fentanyl and bupivacaine in dogs. There is little information on the use of sufentanil in large animals. Due to the greater risk of cardiovascular and respiratory depression sufentanil is rarely used in practice.
Sources: en.wikipedia.org
It also absorbed the separatist Caprivi African National Union (CANU), which was formed to combat South African rule in the Caprivi Strip. Outside the Soviet bloc, Egypt continued training SWALA personnel. By 1964 others were also being sent to Ghana, Algeria, the People's Republic of China, and North Korea for military instruction. In June of that year, SWAPO confirmed that it was irrevocably committed to the course of armed revolution. The formation of the Organisation of African Unity (OAU)'s Liberation Committee further strengthened SWAPO's international standing and ushered in an era of unprecedented political decline for SWANU. The Liberation Committee had obtained approximately £20,000 in obligatory contributions from OAU member states; these funds were offered to both South West African nationalist movements. However, as SWANU was unwilling to guarantee its share of the £20,000 would be used for armed struggle, this grant was awarded to SWAPO instead. The OAU subsequently withdrew recognition from SWANU, leaving SWAPO as the sole beneficiary of pan-African legitimacy. With OAU assistance, SWAPO opened diplomatic offices in Lusaka, Cairo, and London. SWANU belatedly embarked on a ten-year programme to raise its own guerrilla army. In September 1965, the first unit of six SWALA guerrillas, identified simply as "Group 1", departed the Kongwa refugee camp to infiltrate South West Africa. Group 1 trekked first into Angola, before crossing the border into the Caprivi Strip.
=== Current Applications === Voltage gated sodium channels have been used as therapeutic targets in various modes of research, allowing versutoxin to also be used in the process. Some notable diseases versutoxin has been used as a potential therapeutic tool in include: Alzheimer's disease, Parkinson's disease, brain ischemia, glaucoma, and sclerosis. Versutoxin has also been used in biopesticide research. The structure of recombinant Nemertide α-1 (a neurotoxin found in carnivorous marine ribbon worms) was compared against recombinant delta-hexatoxin-Hv1 due to their similar VSGC targeting abilities. However, as of right now, not enough research has been done about the off target effects.
NMR quantum computing uses the spin states of nuclei within molecules as qubits. NMR differs from other implementations of quantum computers in that it uses an ensemble of systems; in this case, molecules.
Sources: en.wikipedia.org
These are a major forum for scientific and medical knowledge exchange and is allied with a large exhibition of In Vitro Diagnostic industry equipment. The Quality and Regulations Committee is particularly focussed on contributing to revisions of International standards such ISO 15189 and ISO 22870 which govern standards in medical laboratories; they also contribute to European Regulations and Directives such as the IVD (In Vitro Diagnostics) Regulations. These regulations and standards ensure quality results are delivered for patient care a key issue in diagnosis and monitoring of health and disease and are under regular international review. The Communications Committee provides information on EFLM activities to members and promotes awareness of EFLM The Profession Committee is responsible for the Register of Specialists in Laboratory Medicine and that applicants meet the standards set for eligibility. The need for comparable attainments of qualification, education and experience is a patient safety issue as patients can freely move across borders. All offices are by election. Member societies have national representatives who vote on behalf of their society. The only automatic office is President who will have been elected as Vice President. Working group members are chosen from member society nominations. The journal published by De Gruyter, Clinical Chemistry and Laboratory Medicine is the EFLM official journal. To date two strategic conferences have been held to advance the profession in Europe:
FUCA is thought to have organized the transition from initial biological systems to mature progenotes. Progenotes were the dominant forms during the Progenote age, when biological systems first originated and assembled. The Progenote age would have happened after the pre-biotic RNA-world and Peptide-world ages, but before the emergence and presence of organisms and mature biological systems like viruses, bacteria and archaea. The most successful progenotes populations were probably the ones capable of binding and processing carbohydrates, amino acids, and other intermediated metabolites and co-factors. In progenotes, there was not complete compartmentalization by membranes and translation of proteins was not precise. Not every progenote had a full metabolism on its own; different metabolic steps occurred in different progenotes. Therefore, it is assumed that there was a community of interacting sub-systems that began to cooperate collectively and eventually culminated in the LUCA.
Grade I: Mild ptosis—The nipple is at the level of the infra-mammary fold and above most of the lower breast tissue. Grade II: Moderate ptosis—The nipple is located below the infra-mammary fold but higher than most of the breast tissue hangs. Grade III: Advanced ptosis—The nipple is below the inframammary fold and at the level of maximum breast projection. Pseudoptosis—The nipple is located either at or above the infra-mammary fold, while the lower half of the breast sags below the fold. This is most often seen when a woman stops nursing, as her milk glands atrophy, causing her breast tissue to sag. Parenchymal Maldistribution—The lower breast tissue is lacking fullness, the inframammary fold is very high, and the nipple and areola are relatively close to the fold. This is usually a developmental deformity.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.